Owc Pharmaceutical Research Stock Performance
The company owns a Beta (Systematic Risk) of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and OWC Pharmaceutical are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days OWC Pharmaceutical Research has generated negative risk-adjusted returns adding no value to investors with long positions. Even with fragile performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 971 K | |
| Total Cashflows From Investing Activities | -28 K |
OWC |
OWC Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 0.01 in OWC Pharmaceutical Research on December 1, 2024 and sell it today you would lose (0.01) from holding OWC Pharmaceutical Research or give up 100.0% of portfolio value over 90 days. OWC Pharmaceutical Research is currently does not generate positive expected returns and assumes 12.9099% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than OWC, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
OWC Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OWC Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as OWC Pharmaceutical Research, and traders can use it to determine the average amount a OWC Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1291
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OWCP |
Estimated Market Risk
| 12.91 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.67 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OWC Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OWC Pharmaceutical by adding OWC Pharmaceutical to a well-diversified portfolio.
OWC Pharmaceutical Fundamentals Growth
OWC Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of OWC Pharmaceutical, and OWC Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OWC Pink Sheet performance.
| Return On Asset | -0.64 | |||
| Current Valuation | 49.75 K | |||
| Shares Outstanding | 497.5 M | |||
| Price To Earning | (12.76) X | |||
| Price To Book | 42.29 X | |||
| EBITDA | (10.25 M) | |||
| Cash And Equivalents | 1.47 M | |||
| Cash Per Share | 0.01 X | |||
| Debt To Equity | 0.15 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (2.5 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 3.55 M | |||
| Retained Earnings | (25.14 M) | |||
| Current Asset | 112 K | |||
| Current Liabilities | 187 K | |||
About OWC Pharmaceutical Performance
Assessing OWC Pharmaceutical's fundamental ratios provides investors with valuable insights into OWC Pharmaceutical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the OWC Pharmaceutical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
OWC Pharmaceutical Research Corp., through its subsidiary, One World Cannabis Ltd., engages in the research and development of cannabis-based medical products. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Ramat Gan, Israel. Owc Pharmaceutical is traded on OTC Exchange in the United States.Things to note about OWC Pharmaceutical performance evaluation
Checking the ongoing alerts about OWC Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for OWC Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OWC Pharmaceutical generated a negative expected return over the last 90 days | |
| OWC Pharmaceutical has high historical volatility and very poor performance | |
| OWC Pharmaceutical has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (10.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| OWC Pharmaceutical Research currently holds about 1.47 M in cash with (2.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing OWC Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OWC Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining OWC Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OWC Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OWC Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OWC Pharmaceutical's pink sheet. These opinions can provide insight into OWC Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for OWC Pink Sheet Analysis
When running OWC Pharmaceutical's price analysis, check to measure OWC Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OWC Pharmaceutical is operating at the current time. Most of OWC Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of OWC Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OWC Pharmaceutical's price. Additionally, you may evaluate how the addition of OWC Pharmaceutical to your portfolios can decrease your overall portfolio volatility.